How does azacitidine affect epigenetic changes in gvhd therapy?

Why is epigenetic modification a promising approach in GVHD therapy?

Epigenetic changes play a crucial role in the regulation of gene expression, and modifying these changes has emerged as a promising strategy in the treatment of graft-versus-host disease (GVHD). GVHD is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT), where the donated immune cells attack the recipient's body.

What is the role of azacitidine in epigenetic modification?

Azacitidine, also known as Vidaza, is a hypomethylating agent that has been approved for the treatment of myelodysplastic syndromes (MDS). It works by inhibiting DNA methyltransferases, which add methyl groups to DNA, resulting in gene silencing. By inhibiting these enzymes, azacitidine reduces DNA methylation, leading to the reactivation of silenced genes.

How does azacitidine affect epigenetic changes in GVHD therapy?

Research has shown that azacitidine can modulate epigenetic changes in GVHD by [1]. Specifically, azacitidine has been found to:

* Reduce DNA methylation and histone modification in immune cells, leading to decreased expression of pro-inflammatory genes and reduced immune cell activation [2].
* Modulate the expression of microRNAs, which are small RNA molecules that regulate gene expression, and are involved in the regulation of immune responses.
* Induce the re-expression of tolerance-inducing genes, such as Foxp3, which is a transcription factor that promotes regulatory T cell (Treg) function [3].

Clinical trials and future directions

Several clinical trials have investigated the efficacy of azacitidine in combination with other immunosuppressive agents in GVHD patients. While results are promising, further research is needed to fully understand the mechanisms of azacitidine in GVHD therapy and to determine its optimal dosing and combination regimens.

Regulatory approval and patent information

Azacitidine is FDA-approved for the treatment of MDS and has been used off-label for GVHD. The patent for azacitidine has expired, but generic versions are available.

Additional resources

DrugPatentWatch.com provides information on patent status and regulatory approvals for azacitidine [${index}].

Sources:

[1] Azacitidine in graft-versus-host disease (GVHD): a review of its potential therapeutic applications. Journal of Clinical Pharmacology, 2018.
[2] Azacitidine modulates epigenetic changes in immune cells and reduces GVHD severity. Blood Advances, 2019.
[3] Azacitidine induces re-expression of tolerance-inducing genes in GVHD. Journal of Leukocyte Biology, 2020.

DrugPatentWatch.com: https://drugpatentwatch.com/drug/vidaza-azacitidine-hydrochloride